Chronic kidney disease (CKD), usually defined as glomerular filtration rate (GFR) < 60 mL/min/1.73 m 2 for at least 3 months, 1 affects $7% of adults in the United States.
existed from the same data source, the most recent was reviewed. Finally, abstracts from international conferences were manually searched for relevant publications.
Vitamin K Antagonists Pharmacology in ESRD
Vitamin K antagonists (VKAs), including warfarin, reflect the mainstay of treatment and prevention of thromboembolic disease in ESRD. Warfarin has a near 100% bioavailability, and reaches peak concentration within 4 hours of absorption. Elimination of warfarin is almost entirely via metabolism, and renal clearance is negligible. 12 However, in patients with ESRD, nonrenal clearance is diminished through downregulation of cytochrome P450 gene expression. 13 A consequent increase in the S/R enantiomer ratio 14 is the putative explanation for three important observations in ESRD patients: (1) 
Utilization Patterns in ESRD
The effectiveness and safety of VKA among patients with ESRD and AF is highly debated, 21, 22 as reflected in the wide variability of VKA use among patients with ESRD in different high-income countries. 23 Similarly, studies from the United
States preceding market availability of the direct oral anticoagulants (DOACs) report a 15.5 to 62.3% prevalence of VKA use in patients on dialysis with incident AF. 16, 24 One further concern with VKA use for stroke prevention is low persistence over time, or early discontinuation. 25 Indeed, almost half of dialysis patients with AF initiated on VKA were found to discontinue the drug within less than 9 months of use and without switching to DOACs.
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Safety in ESRD
The presence of ESRD confers a bleeding diathesis independent of oral anticoagulation, manifesting as major, but also as nonmajor bleeding events. 17 In hemodialysis patients, repetitive activation of platelets is thought to lead to platelet "exhaustion" and consequent dysfunction. 26 Several studies have been published on bleeding risk with VKA among patients with ESRD (►Table 2). While differing in study design and methodology, most of the larger (> 100 VKA users) studies reported major bleeding rates of 10 per 100 person-years or higher. In comparison, the pivotal clinical trials with DOACs, which excluded patients with severe CKD or ESRD, reported bleeding rates of $3 per 100 person-years in the VKA arm.
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This comparison emphasizes the bleeding diathesis in ESRD rather than the comparative risk of bleeding with VKA versus no use, which varies with reports.
A further safety concern with VKA use in ESRD is increased risk of calcific uremic arteriolopathy (or calcific vasculopathy), which leads to ischemic skin necrosis. 41 In the United States, the 75-mg dose was used in up to 3% of dialysis patients with AF who were being anticoagulated shortly after its approval. 42 However, the 
Safety in ESRD
In the setting of a closely monitored phase-I study, three doses of dabigatran (150, 110, and 75 mg once) in hemodialysis patients were associated with only one minor bleeding. 38 Data from shortly after the approval of dabigatran in the United States indicate very high rates of major and nonmajor bleeding with its use in hemodialysis patients (►Table 4). 42 While these data may reflect erroneous, early use, current data still suggest 39.4% of dabigatran users for AF who had a renal indication for dose reduction were still receiving the standard dose. 45 However, as dabigatran remains contraindicated in ESRD and is seldom used off-label in this population, it is unlikely that more population-based safety data on dabigatran in ESRD will be published.
Rivaroxaban Pharmacology in ESRD
Rivaroxaban, a factor Xa inhibitor, has a renal clearance of 66% after oral ingestion. Nevertheless, 36% of ingested rivaroxaban is excreted unchanged in the urine, indicating the renal clearance contribution out of total clearance (►Table 1). Direct Oral Anticoagulants in End-Stage Renal Disease Klil-Drori, Tagalakis In Europe, rivaroxaban is contraindicated in ESRD. 54 As of late 2015, rivaroxaban use was prevalent in 0.8% of dialysis patients on anticoagulants for AF in the United States. 43 Similar to dabigatran, 41.3% of the non-ESRD patients with renal indication for dose reduction were overdosed. 45 However, the large majority of rivaroxaban users with ESRD were receiving a 15-mg dose. 42 Finally, in patients with severe CKD there has been a marked increase in the use of rivaroxaban in the United States.
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Safety in ESRD
Very sparse information exists regarding the safety of rivaroxaban in ESRD patients, and no data on the 10-mg dose. The single study that examined the use of the 15-and 20-mg doses had a very short mean follow-up of 106 days (►Table 4).
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Likely due to inappropriate use, a major bleeding rate of 68.4 per 100 person-years was recorded in this population. 42 This rate is more than 18-fold higher than the rate observed in patients who experienced worsening renal function during the ROCKET-AF trial.
55
Apixaban Pharmacology in ESRD
Between 24.5 and 28.8% of the parent drug apixaban, a factor Xa inhibitor, is recovered in the urine after oral ingestion (►Table 1). 56 After intravenous infusion, renal clearance contributes 17 to 30% of the total drug clearance. 57 Renal function is an important predictor of steady-state drug exposure, which occurs after 3 to 4 days. Thus, patients with moderate renal impairment are likely to have a 70% higher AUC at steady state at any apixaban dose. 58 In a study with eight hemodialysis patients receiving a single 5-mg dose, the AUC of apixaban was increased by 36% compared with healthy subjects. Further, dialysis has been found to have a marginal effect on apixaban exposure, reducing the maximal concentration by 13%. 59 Thus, significant accumulation of apixaban at steady state was demonstrated in a subsequent study with six hemodialysis patients who received 2.5 mg apixaban twice a day for 7 days. 60 This study is important in that it showed that the steady-state AUC and minimal concentration of apixaban at 2.5 mg twice a day taken by hemodialysis patients were well within the range in healthy subjects taking the 2.5-mg dose. 58, 61 However, the effectiveness of such a regimen may be questioned, as these values fall below the 10th percentile of the 5 mg twice a day dose in normal subjects. Finally, the same six hemodialysis patients underwent a washout period and then received 5 mg apixaban twice a day for 7 days with a consequent AUC and minimal concentration which were more than twice those seen in healthy subjects.
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Utilization in ESRD
Apixaban was first approved by the FDA for AF in December 2012. The original label recommended dose reduction to 2.5 mg twice a day for patients with at least two factors out of: serum creatinine ! 1.5 mg/dL, age ! 80, and weight 60 kg.
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Following the single-dose pharmacokinetic study mentioned above, the label was changed in January 2014 such that the 5-mg twice a day dose was recommended in ESRD patients who are not older adults or underweight (►Table 3). 63 Of note, in direct reference to the findings from the steady-state study, a recommendation has been made to reconsider the 5-mg dose in hemodialysis patients. 52 Concurrently, the use of apixaban is not approved in ESRD patients in Europe.
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A large retrospective cohort study from the United States that excluded patients with ESRD has demonstrated that among patients with AF receiving apixaban with a renal indication for dose reduction, overdosing was very common at 48.5%; importantly, overdosing was associated with doubling of major bleeding rates. 45 Further, among patients without renal indication for dose reduction, 16.5% were underdosed; such underdosing was associated with an increased risk of stroke (hazard ratio, 4.87; 95% confidence interval, 1.30-18.26). Apixaban has been adopted very rapidly in the United States among patients with hemodialysis and AF, and has reached a point prevalence of 10.5% in this population in October 2015. 43 There is currently paucity of information on utilization of off-label DOACs in the severe CKD or ESRD population in Europe. Nonetheless, among the DOACs, it appears that a larger proportion of apixaban users with AF have baseline CKD. 65, 66 In a survey among European electrophysiology centers, apixaban was indicated as the preferred anticoagulant in moderate CKD, and the lack of data on patients with severe CKD and/or RRT was emphasized.
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Safety in ESRD
Bleeding risk with apixaban in ESRD has been assessed in three studies to date (►Table 4). Two of these studies included only inpatient follow-up. 68, 69 With limited follow-up and selection of only events during admission, any rates of major bleeding in these studies are not comparable to clinical trials. In the third study, matched cohorts of patients with severe CKD who used apixaban or VKA were followed for major and clinically relevant nonmajor bleeding; each cohort comprised 73 patients (27 ESRD). 70 Apixaban users received 2.5 mg twice a day primarily (61.6%) and were followed for 369 days. There were 9.5 major bleeding events per 100 person-years, which is 3. 
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These recommendations by the two regulatory authorities were based on population pharmacokinetic data only, as very few participants with GFR < 50 mL/min/1.73 m 2 were included in the ENGAGE-AF TIMI 48 trial. 78 To date, there are few reports on the utilization of edoxaban in the ESRD population, and, by late 2015, it was probably negligible in the United States.
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Safety in ESRD
A clinical trial in Japan reported on 50 patients with GFR 15 to 30 mL/min/1.74 m 2 who used edoxaban 15 mg daily in a nonrandomized fashion (►Table 4). 79 No major bleeding occurred during a 100-day follow-up.
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Conclusion
VKAs are the most widely used oral anticoagulant among AF patients with ESRD. However, there are abundant reports on excessive bleeding risk associated with its use, as well as challenges in attaining therapeutic anticoagulation. These may have triggered rapid adoption of DOACs among ESRD patients in the United States, which initially may have led to inappropriate dosing and excessive bleeding. While apixaban and rivaroxaban have to date expanded labeling which allows use in ESRD, the dosing is based on single-dose studies which may have underestimated drug accumulation and foreseeable harm. Subsequently, steady-state studies have indicated in both cases a reduced dose. While recommending these doses for use in ESRD patients would align with current safety data, their effectiveness in preventing stroke in AF and recurrent VTE remains to be established. Nevertheless, it is very likely that with further increased use of DOACs in ESRD, more population-based safety and effectiveness data will allow informed dosing and choice of oral anticoagulant.
